Current Osteoporosis Reports

, Volume 7, Issue 1, pp 1–2

Zoledronic acid reduces recurrent clinical fracture in patients with hip fracture

  • Stuart L. Silverman
Clinical Trials Report


  1. 1.
    Black DM, Delams PD, Eastell R, et al.: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809–1822.PubMedCrossRefGoogle Scholar
  2. 2.
    Colón-Emeric C, Messenbrink P, Lyles K, et al.: Potential mediators in the reduction of mortality with zoledronic acid after hip fracture [abstract 1030]. Presented at the 30th Annual Meeting of the American Society for Bone and Mineral Research. Montreal, Quebec, Canada; September 12–16, 2008.Google Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  • Stuart L. Silverman

There are no affiliations available

Personalised recommendations